[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2 ... - ACS Publications

Subscriber access provided by Duke University Libraries

Article

Discovery and Development of N-[4-(l-Cyclobutylpiperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride (SUVNG3031): A Novel, Potent, Selective and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity Ramakrishna Nirogi, Anil K. Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Veena Reballi, Thrinath Reddy Bandyala, Sangram Keshari Saraf, Kumar Bojja, sravanthi manchineella, Pramod Kumar Achanta, Kiran Kumar Kandukuri, Ramkumar Subramanian, Vijay Benade, Raghava Choudary Palacharla, Pradeep Jayarajan, Santoshkumar Pandey, and Venkat Jasti J. Med. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jmedchem.8b01280 • Publication Date (Web): 10 Jan 2019 Downloaded from http://pubs.acs.org on January 11, 2019

Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Page 1 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Journal of Medicinal Chemistry

Discovery and Development of N-[4-(lCyclobutylpiperidin-4-yloxy) phenyl]-2-(morpholin4-yl) acetamide dihydrochloride (SUVN-G3031): A Novel, Potent, Selective and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity Ramakrishna Nirogi*, Anil Shinde, Abdul Rasheed Mohammed, Rajesh Kumar Badange, Veena Reballi, Thrinath Reddy Bandyala, Sangram Keshari Saraf, Kumar Bojja, Sravanthi Manchineella, Pramod Kumar Achanta, Kiran Kumar Kandukuri, Ramkumar Subramanian, Vijay Benade, Raghava Choudary Palacharla, Pradeep Jayarajan, Santoshkumar Pandey and Venkat Jasti Discovery Research, Suven Life Sciences Ltd, Serene Chambers, Road-5, Avenue-7, Banjara Hills, Hyderabad 500 034, India *Corresponding Author Tel.: +91-40-23556038; Fax: +91-40-23541152; e-mail: [email protected]

ACS Paragon Plus Environment

Journal of Medicinal Chemistry 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Keywords-Histamine-3 inverse agonist, Structure-activity relationship, Orexin-B-SAP lesioned rats, Wake promoting activity

ABSTRACT: A series of chemical optimizations guided by in vitro affinity at histamine H3 receptor (H3R), physico-chemical properties and pharmacokinetics in rats resulted in identification of N-[4-(1-Cyclobutyl-piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake promoting effects with decreased REM sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability and pharmacokinetics, and long term safety studies in animals have been successfully completed without any concern for further development.

INTRODUCTION Narcolepsy is a life-long neurological sleep disorder largely characterized by excessive daytime sleepiness (EDS), sleep paralysis, cataplexy, and hallucinations and disrupted nighttime sleep. The disease is segmented into two categories i.e., narcolepsy with cataplexy (Type 1) which is characterized by sudden loss of muscle tone and narcolepsy without cataplexy (Type 2).1,2 Narcolepsy has substantial impact on the quality of life including social functioning, family relationships, academic performance as well as burden on the associated healthcare resource utilization and costs.3,4


Page 2 of 51

Page 3 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


The histamine 3 receptor (H3R) is a member of a seven transmembrane-spanning G-protein coupled receptor (GPCR) family5 and it functions both as a presynaptic autoreceptor and a heteroreceptor. As an autoreceptor it regulates the release of histamine in the brain, particularly in the cortex, striatum, hippocampus, amygdala and substantia nigra. H3R as an inhibitory heteroreceptor, modulates the release of key neurotransmitters like acetylcholine, dopamine, norepinephrine, and serotonin. H3R also associated with many important functions including arousal, regulation of sleep-wake cycle, immune modulation, satiety and cognition.6-8 Wakepromoting effect of H3R inverse agonists most likely depends on histaminergic autoreceptormediated modulation of histaminergic neurotransmission. The anti-cataplectic effect seems to involve not only the histaminergic but also other neurotransmitter systems like dopamine and norepinephrine that are controlled by histamine 3 heteroreceptors.9,10 A number of H3R antagonists/inverse agonists demonstrated wake-promoting effects in several animal species. H3R antagonists/inverse agonists did not show wake promoting effects in H3R knockout mice providing evidence for the involvement of the receptor in wake promoting effects.8,11 Previously reported imidazole based H3R antagonist thioperamide increased the wakefulness and decreased NREM and REM sleep in tested rats and cats12,13 but unlike amphetamine and caffeine, its wake promoting effects were not accompanied by behavioral excitation and sleep rebound.8,14,15 Other H3R antagonists like ciproxifan and carboperamide were also reported to increase the wake promoting effects and were reported to decrease NREM sleep in rats.16,17 The European Medicines Agency (EMA) has granted a marketing authorization valid throughout the European Union for pitolisant (Wakix), a H3R antagonist for the treatment of narcolepsy with or without cataplexy.18 Thus, H3R offers a unique platform for the treatment of sleep-wake disorders without having stimulant activity.



In the past,19,20 researchers have optimized the parameters like hERG and phospholipidosis by modulating the physico-chemical properties like lipophilicity (LogP, LogD) and basicity (pKa). A diamine based H3R antagonist, JNJ-5207852was reported to possess high brain residence time and induced phospholipidosis.21 A related wake promoting compound (JNJ-7737782) was reported subsequently with substantially reduced pKa and reduced half-life in rats.22 Letavic et. al. recently demonstrated23 that, improved human pharmacokinetic profiles can be obtained by fine tuning the physicochemical properties of H3R ligands in order to reduce tissue retention time and half-lives. Hudkins et. al. have reported24 the increased wake duration for CEP-32215 in rat EEG model at 3 to 30 mg/kg p.o. indicating its wake promoting properties. Irdabisant, a H3R antagonist/inverse agonist, reported25 to increase wake promoting activity, decreased slow-wave and rapid-eye movement sleep dose dependently in the tested doses of 3–30 mg/kg p.o. In the past, we have published our initial efforts in identifying novel H3R antagonists.26 Starting from a hit with moderate potency at H3R, a series of six membered cyclic benzamide (lactam) derivatives, exemplified by 2-(1-cyclobutyl piperidin-4-yl)-6-(1-cyclobutyl piperidin-4yloxy)-3,4-dihydro-2H-isoquinolin-1-one (Compound I, Figure 1) were designed, synthesized and evaluated. Compound I exhibited potent in vitro affinity (hH3 Ki = 0.8 nM) at H3R. However, it exhibited delayed absorption accompanied by higher volume of distribution (Vdss) and extended half-life in rats. The Compound I had low brain penetration (Cb/Cp ratio of ~0.40) and also had phospholipidosis inducing potential at concentrations above 20 µM (Supporting information). The ADME features for this compound were less than ideal given the role of H3R antagonist’s in sleep/wake cycle, vigilance and attention. This prompted us to work on a chemically diverse scaffold distinct from lactam based Compound I with pharmacokinetic (PK) profiles more consistent with our goal of developing a rapidly absorbing, shorter-acting clinical


Page 4 of 51

Page 5 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


candidate devoid of phospholipidosis potential. The optimization of chemical scaffold was mainly driven by H3R affinity, modulation of physico-chemical properties and PK properties in rats. Opening of the rigid ring in compound I to obtain the flexible linker resulted in compounds 9a–9f (Series A, Figure 1), transposition of the amide functionality to obtain the acetamide functionality resulted in compounds 17a–17ah (Series B), modulation of ether linkage in the western domain resulted in compounds 26a–26f (Series C), substitution on acetamide nitrogen resulted in compounds 27a and 27b (Series D). O N

N O Compound I

O R1

Ring opening Rearranging amine ring

N

2

R O

3

1 4

Western domain

N

Central core

N H

R1

N

H N

O Series A (9a-9f)

R1

2

R N

O

R2

Eastern domain

O N H

R1

2

R N

N R2

R2

Series C (26a-26f)

R2

O

Transpose amide Reduce linker

R2 N

N R2 3 R Series D (27a-27b)

Series B (17a-17ah)

Figure 1. Design strategy Chemistry. The general synthetic strategy used for the preparation of compounds is summarized in Schemes 1−5. The starting materials 1, 2, 5a–5c, 8a–8c (Scheme 1), 12a–12d, 16a–16q (Scheme 2), 18a–18e (Scheme 3) and 24a–24f (Scheme 4) were commercially procured.



Page 6 of 51

Scheme 1. Synthesis of 9a–9fa OTs

O OCH3

O Boc

a

+

OCH3

N Boc 2

HO 1

N

3 O Boc

c

OH

N

N H

R2 N

R2

d

O

5a/5b/5c

O

b

O

O Boc

N

6a-c

4 R2 N

O HN 2HCl

N H O

O

e

R2

R1

8a/8b/8c

N

N H O

7a-c

R2 N

R2

9a-f

O N

N

N

O

NH2

NH2

NH2

(5a)

(5b)

(5c)

(8a)

O

O

(8b)

(8c)

aReagents

and conditions: (a) K2CO3, DMF, 6 h, 110-120 ºC, 72%; (b) LiOH.H2O, THF:H2O, rt, 6 h, 85%; (c) PyBop, Et3N, DCM, 12 h, rt, 65-75%; (d) IPA.HCl: IPA, 3 h, rt, 85-95%; (e) NaBH(OAc)3, Et3N, 1, 2-dichloroethane, 15 h, rt, 80-85%.


Page 7 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Scheme 2. Synthesis of 17a–17k, 17q–17ac and 17aha OH

OH a

b

8a/8b/8c

N H

N R1 11a-11c

10

12a/12b

R1

R1

4

N

NO2

13a; R1 = cyclopentyl, R = H 13b; R1 = cyclobutyl, R = H 13c; R1 = isopropyl, R = H 13d; R1 = cyclobutyl, R = 2-F

11a; R = cyclopentyl, 11b; R1 = cyclobutyl, 11c; R1 = isopropyl

R

R

O d

N

12c/12d

NH2

c

3

13a-13d

1

O

R

2

O 1

N

R1

X

O

Y

N H

14a-14d

17w-17x

e

O R

1

O

N

Cl

N H

15a-15d

f

R1

16a-16q

N

F

O N N H 16j

N H 16d

N H 16c O

O N N H 16k

R2

NO2

F N

R

16a

N H

R2 N

17a-17k, 17q-17ac, 17ah

F N H 16b

O

2HCl

16a-q N H

R

O

R

N H 16e

N H 16f

N H 16g

F

N H 16i

N H 16h

O O S

O

N H

N H

N H

16l

16m

16n

HO HO

N H 16o

O

O N H 16p

N H 16q

aReagents

NO2

F 12a

OH

N

F

12b

O

N

N

HO

HO 12c

12d

and conditions: (a) NaBH(OAc)3, Et3N, 1, 2-dichloroethane, 24 h, rt, 90-95%; (b) NaH, THF, rt, 5 h, 75-80%; (c) Fe, NH4Cl, Ethanol:H2O, reflux, 4 h, 84-88%; (d) PyBop, Et3N, DCM, rt, 15 h, 50-55%; (e) Chloroacetyl chloride, K2CO3, THF, 10 ºC to  5 ºC, 2 h, 95-98%; (f) i) Methanol, reflux, 4 h, 88-93%; ii) IPA.HCl: IPA, rt, 3 h, quantitative.



Page 8 of 51

Scheme 3. Synthesis of 17l–17p and 17ad–17aga OTs 2

HO

R 3

1 4

a

+

N Boc

NO2

18a-18e

R

O Boc

b

N

N

Boc

NO2

NH2

19a-19e

2

R

O

20a-20e

18a-18e, where R is; 18a=3-CH3, 18b=3-CF3, 18c=3-F, 18d=3-OCH3, 18e=H R

O

c Boc

O

N

d Cl

N H

16c/16d/16e/16n

Boc

e

N H

R2 N

R2

22a-22j

R R2 N

O

HN

O

N

21a-21e

O

R

O

N H

R2

R

2

O

f R1

8b

N

O

3

1 4

N H

R2 N

R2

17l-17p & 17ad-17ag

23a-23j

aReagents

and conditions: (a) K2CO3, DMF, 110-120 ºC, 6 h, 80-85%; (b) Fe, NH4Cl, Ethanol:H2O, reflux, 4 h, 85-88%; (c) Chloroacetyl chloride, K2CO3, THF, 10 °C to  5 ºC, 2 h, 90-95%; (d) K2CO3, DMF, 75-80 ºC, 4 h, 75-80%; (e) IPA.HCl: IPA, rt, 3 h, then aq. NaOH, 8590%; (f) NaBH(OAc)3, Et3N, 1, 2-dichloroethane, 24 h, rt, 75-80%. Scheme 4. Synthesis of 26a–26fa R1

R1

a

R1

O Cl

N H

NH2 24a-24f

O

b 16d/16n

25a-25f

N H

R2 N

R2

26a-26f

R1 = O

O

N

N

R

R

N

N

N

N N

a

b

c

d

e

f

and conditions: (a) Chloroacetyl chloride, K2CO3, THF, 10 ºC to  5 °C, 2 h, 7075%; (b) Methanol, reflux, 6 h, 85-90%. aReagents


Page 9 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Scheme 5. Synthesis of 27a–27b a O N

O N H

O N

O

a

N

17v aReagents

O N R3

O N

27a-27b

and conditions: (a) CH3I/C2H5I, NaH, DMF, 65-70 ºC, 4 h, 65%.

The tosyl group of compound 2 was displaced with methyl 4-hydroxybenzoate (1), to obtain ester compound 3 which on hydrolysis with LiOH afforded acid compound 4. The acid compound 4 was reacted with various amines, 5a–5c, in presence of PyBop to obtain Bocprotected carboxamide derivatives 6a–6c, which upon Boc deprotection with isopropanolic HCl in isopropanol gave compounds 7a–7c respectively. Reductive amination of compounds 7a with 8a, 8b and 8c gave compounds 9a, 9e and 9f, whereas reaction of compound 7b with 8b yielded compound 9b. The reductive amination of 7c with 8b and 8c provided compounds 9c and 9d respectively (Scheme 1). Reductive amination of compound 10 with carbonyl compounds 8a−8c afforded N−alkylated compounds 11a−11c respectively. Nucleophilic substitution of 12a with 11a−11c in presence of NaH afforded the nitro compounds 13a−13c respectively, while 12b on reaction with 11b gave intermediate 13d. Reduction of nitro group in compounds 13a−13d with activated iron yielded compounds 14a−14d, which on further reaction with chloroacetyl chloride and potassium carbonate afforded compounds 15a−15d respectively. PyBop mediated acid-amine coupling of 14b with 12c and 12d yielded compounds 17w and 17x respectively. Amination of 15a with 16c, 16e and 16n gave target compounds 17i, 17j and 17ac while reaction of 15b with 16a−16h gave 17a−17h respectively. Reaction of 15b with 16i−16q gave 17q−17aa respectively whereas



compound 15c on reacting with 16e and 16n gave compounds 17k and 17ab respectively. Reacting compound 15d with 16n afforded compound 17ah (Scheme 2). Alternate synthetic scheme was followed for getting the target compounds ‘17’ having substitution on central aromatic ring. Variously substituted aromatic nitro compounds (18a–18e) were reacted with compound 2 to obtain compounds 19a–19e which on nitro group reduction followed by chloroacetyl chloride reaction yielded compounds 21a–21e. Amination of compounds 21a with 16c, 16d, 16e and 16n gave compounds 22a, 22b, 22c and 22g respectively while amination of compound 21b with 16c, 16e and 16n gave compounds 22d, 22e and 22h respectively. Amination of compounds 21c, 21d, and 21e with 16n yielded compounds 22f, 22i and 22j respectively. The compounds 22a–22j on Boc deprotection yielded 23a–23j respectively. Reductive amination of 23a, 23b, 23c,and 23g with 8b resulted in target compound 17l, 17m, 17n and 17ae while 23d, 23e, 23f, 23h and 23i on reductive amination with 8b gave 17o, 17p, 17ad, 17af and 17ag respectively (Scheme 3). Substituted aromatic amines (24a–24f) on reaction with chloroacetyl chloride yielded compounds 25a–25f. Amination of 25a–25b with 16d gave target compounds 26a–26b whereas 25c–25f on amination with 16n yielded target compounds 26c–f respectively (Scheme 4). Alkylation of amidic ‘NH’ of compound 17v delivered compounds 27a and 27b (Scheme 5). The compound 28 was synthesized according to Scheme 2 starting with 1-fluoro-2nitrobenzene whereas the compound 29 was synthesized according to Scheme 3 starting from 3nitrophenol. The scope of structure activity relationship (SAR) using Compound I (LogP = 4.0, hH3 Ki = 0.80 nM) was limited because of the cyclic amide nature of its central core (3,4-dihydro-2Hisoquinolin-1-one). Hence the rigid benzamide series was modified and rearranged to a flexible


Page 10 of 51

Page 11 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


open chain benzamide series (Series A, Figure 1). This scaffold was synthetically accessible and sufficiently versatile to support lead optimization. Compounds 9a–9f were synthesized and evaluated in in vitro radioligand binding technique using recombinant histamine H3R,27 the results of which are shown in Table 1. In vitro affinity of 10000

N

H

aThe

affinity of the test compounds were determined using in-vitro radioligand binding assay using recombinant human H3R membrane and [3H]-(R)-α-methylhistamine radioligand. Values are mean of two independent experiments. Compounds 17c, 17e, 17h, 17j, 17k, 17l, 17n, 17o, 17s, 17v, 17u, 17y, 17aa, and 17ab are dihydrochloride salts while 9c, 17f and 17w are L-(+)tartrate salts. Remaining compounds are free bases.



Page 16 of 51

Table 2. hH3R radioligand binding dataa R1

O N H

R2 N

R1 R

R2 N

O

2

N R3 Series D (27a-27b)

Series C (26a-26f)

R2

R2 N

Comp. Series R1 No

R2

R3

l

m

n

hH3R Ki (nM)

-

-

-

-

1455

-

-

-

-

915

R

26a

C

O

N

26b

C

O

N

26c

C

26d

C

26e

C

26f

C

N R

N

N

N

O

-

-

-

-

114.5

N

O

-

-

-

-

3572

N

O

-

-

-

-

107.6

N

O

-

-

-

-

532.1

N

O

CH3

-

-

-

4.89

N

O

C2H5

-

-

-

10.8

R

N R

N N

N

O

27a

D

N

O

27b

D

N

O

28

N

O

HN N

O


>10000

Page 17 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


O

29

N

H N

N O

O

212.1

Pitolisant

27.6

Imetit

0.30

aThe

affinity of the test compounds were determined using in-vitro radioligand binding assay using recombinant human H3R membrane and [3H]-(R)-α-methylhistamine radioligand and are mean of two independent experiments. Pitolisant is HCl salt. Remaining compounds are free bases. To assess the impact of moving from benzamide to acetamide series on the pharmacokinetic parameters, select compounds 17c, 17e and 17l were evaluated in rat PK study. Unfortunately, all these compounds exhibited the same shortcomings as observed with compounds 9a and 9b, such as delayed absorption with higher Vdss and extended half-life (Table 4). However, to our delight, this modification resulted in improved brain exposures for compound 17e (Cb/Cp= 36.6) and 17l (Cb/Cp = 1.20). At this point, in vitro phospholipidosis inducing potential for the select potent compounds (17c, 17e and 17f) was assessed by fluorometric assay as the phospholipidosis phenomenon has been reported to be one of the reason for attrition of the earlier reported H3R ligands.20 Compounds 17c and 17e had shown strong phospholipidosis inducing potential at 100 µM while compound 17f had shown strong phospholipidosis inducing potential at 50 µM (supporting information). The cationic amphiphilic compounds that possess relatively high pKa (basicity) and high LogP (lipophilicity) are known to induce phospholipidosis. Ploemen et al. reported28 use of simple physicochemical properties ClogP and pKa to identify compounds with phospholipidosis inducing potential. The discovery of this acetamide core as a novel, potent H3R chemotype with improved brain penetration properties provided us additional scope for further optimization to modulate the physicochemical properties without affecting the in vitro potency.



In light of literature precedence and the results obtained above, the efforts were made in replacing piperidine ring in compound 17e with various heterocyclic/heteroaryl rings in order to reduce the lipophilicity (by lowering LogP) and modulate the pKa. Theoretically, the introduction of hetero atom increases the polarity thereby decreases LogP and modulates the pKa of the compound. Increase in polarity of the compound may also reduce Vdss and terminal halflife thereby decreases the risk of phospholipidosis potential. This understanding led to the synthesis of compounds 17q–17ac and 23j. Compounds 17q and 17r were prepared by replacing piperidine with alkyl substituted homopiperazines. Both compounds exhibited H3R affinity comparable to its parent analog 17e. Similar results were obtained for compounds 17s and 17t where the piperidine is replaced by piperazine with terminal nitrogen substituted with carbamate group as in compound 17s and acyl group as in compound 17t suggesting that placement of larger groups on the terminal piperazine nitrogen is also tolerated. Compounds 17u, 17v, 17w and 17x with substitutions like thiomorpholine 1,1-dioxide, morpholine, 4-pyridylmethyl and 3pyridylmethyl respectively were well tolerated though the in vitro affinity of these derivatives was 3-4 fold less as compared to compound 17e. Compounds 17y, 17z and 17aa with introduction of heteroatom onto the ring were also tolerated with potent in vitro affinity at H3R. In order to further expand the scope of SAR, the cyclobutyl group on the piperidine of compound 17v was replaced with isopropyl, cyclopentyl and hydrogen to obtain compounds 17ab, 17ac and 23j respectively. Compound 17ab showed similar in vitro affinity as that of 17v while 17ac is 34 fold less potent than 17v whereas compound 23j found to be inactive suggesting alkyl substitution on nitrogen is essential. Few more analogues 17ad–17ah with ortho/meta fluoro, methyl, trifluormethyl and methoxy substituted phenyl ring were prepared. Compounds 17ad and 17ae with fluoro and methyl substituent respectively at ortho position were fivefold less


Page 18 of 51

Page 19 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


potent than their parent compound 17v while compounds 17af and 17ag with ortho –CF3 and – OCH3 substituents respectively were ~8 fold less potent. Compound 17ah with fluoro substitution at meta position was also ~8 fold less potent than the parent analog 17v. It is evident from the results obtained as shown in Table 3, the introduction of the polar rings as in compound 17v and 17ab resulted in reduction of LogP (by a unit) and in pKa (~half log unit) as against their counterparts 17e and 17k respectively. Table 3. Measured physicochemical properties of select compounds LogP

LogD (at pH 7.4)

pKa1 pKa2

17c

3.2

1.2

9.1 and 7.4

17e

3.7

1.3

9.2 and 7.5

17f

4.3

1.7

9.2 and 7.6

17k

3.4

1.6

9.4 and 7.2

17v

2.2

0.4

8.5 and 4.9

17y

2.1

0.6

8.9 and 6.4

17ab

1.8

0.5

8.9 and 5.0

Comp. No

and

The detailed rat pharmacokinetic profile for compounds 17v, 17w, 17y and 17ab is given in Table

4.

As

envisaged,

the

PK

profile

of

compound

17y

having

polar

2-

hydroxymethylpyrrolidine substituent showed shorter half-life (LogP = 2.1; i.v.t1/2 = 1.88 h) as compared to pyrrolidine compound 17c (LogP = 3.2; i.v.t1/2 = 42.87 h). Also noteworthy is the reduction in Vdss for compound 17y (9.0 L/Kg) as against compound 17c (34.78 L/Kg) that complements its shorter half-life. Similarly, pyridine substituted compound 17w also showed shorter half-life (i.v.t1/2 = 1.12 h). However, both of compounds 17w and 17y showed poor brain exposures. The morpholine substituted analogues 17v and 17ab have shown favorable rat PK



Page 20 of 51

profile as compared to their piperidine analogue 17e and 17k respectively. Unlike compound 17e, compounds 17v and 17ab showed rapid absorption, reduced half-life, reduced Vdss and excellent bioavailability. We tentatively attributed this observation to a reduced Vdss which is likely driven by the reduction in LogP and pKa of 17v and 17ab compared to 17e and 17k respectively (Table 3). The brain to plasma (Cb/Cp) ratio for compound 17v was ~1 while that for compound 17ab was relatively less at 0.33. The in vitro phospholipidosis inducing liability was also assessed for both of compounds 17v and 17ab by fluorometric assay. Gratifyingly and in the expected lines, both of the compounds did not show any phospholipidosis inducing potential or any cytotoxicity up to the highest tested concentration of 300 µM (supporting information). In rodent and non-rodent long term in vivo safety studies done on compound 17v, phospholipidosis was not observed up to the tested doses and thus complementing the in vitro observation. In summary, these findings showed that the design strategy of modulating physicochemical properties (lowering LogP and moderate reduction of pKa) by introducing polar substituents was a viable approach for the identification of compound devoid of phospholipidosis without impacting the in vitro affinity and potency. Compounds 26a–26f were prepared (Series C) in order to understand the western domain SAR of the “N-cyclobutyl-4-hydroxypiperidine” motif in driving potency across this series. Compounds with alternate cyclic amines like morpholin-4-yl (26a) or morpholin-4-ylmethyl (26b),

pyrrolidin-1-ylmethyl

(26c),

2-methyl-pyrrolidin-1-ylmethyl

(26d),

2-(2-methyl-

pyrrolidin-1-yl)-ethyl (26e) and 4-cyclobutyl-piperazin-1-yl (26f) were made. The in vitro affinity of all these compounds was >100 nM indicating the importance of N-cyclobutyl-4hydroxypiperidine for H3R affinity.


Page 21 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


N-alkylation on compound 17v resulted in compounds 27a and 27b (Series D). This modification though tolerated in terms of in vitro affinity, however the rat half-life (~6 h) was 3 times more for 27a than the half-life of 17v. At the end, the position of the ether linkage with respect to acetamide group was explored. Changing of the position from para to ortho or meta was not well tolerated and compounds 28 (ortho substitution) and 29 (meta substitution) turned out to be inactive at H3R. The radioligand binding affinity of Pitolisant at H3R was found to be 27.6 nM when tested in our in-house radioligand binding assay. In comparison, under the similar tested conditions 17v has a Ki of 8.73 nM. The reported Ki value10 for the Pitolisant for human recombinant H3R is 2.7 nM. In our in house study we have used [3H]-R--methyl histamine while in the reported study the radioligand used was [125I]-Iodoproxyfan. We assume that the probable disparity in the Ki value of Pitolisant might be due to the difference in radioligand employed and their pharmacological properties. In the same study, the reference compound imetit shown a Ki of 0.3 nM which is in agreement with literature reports. Table 4. Pharmacokinetic properties of compound set in rats

Comp. No

AUC AUC0-24hr Tmax (ng*h/mL) (ng*h/mL) (h) p.o. i.v.

Compound I

1429

9a

205

9b

1743

Vdss (L/Kg)

CL t1/2 (mL/min/kg) (h) i.v.

i.v.

2

F (%)

Cbrain/Cplasma at 1 h (total)

27

0.41

6

13

174

3.33

135.25

156

13.18

48

NT

347

255

1.33

45

51

13.81

46

0.07

17c

556

757

3.33

34.78

13.57

42.87

17

NT

17e

1387

1855

3.33

20

30

11.18

37

36.6

23.49



Page 22 of 51

17l

1349

3345

2.17

27.03

13.21

26.31

20

1.20

17v

626

263

0.42

5

63

1.45

79

0.93

17w

545

145

0.25

7

113

1.12

125

0.16

17y

63

212

0.58

9

67

1.88

10

0

17ab

850

340

0.42

6

48

2.04

85

0.33

aFasted

male Wistar rats, Vehicle used: water for injection for both p. o. and i.v. routes. Dosing Volumes: 10 mL/kg for p.o. and 2 mL/kg for i.v.; NT: Not tested

Having zeroed in on compound 17v, the most optimized one among the tested lot, the PK of compound 17v was evaluated in Beagle dogs (at 3 mg/kg p.o. and 1 mg/kg i.v., dose). Compound 17v showed rapid absorption (Tmax between 0.25 – 1.00 h) with high oral exposure (AUC0-t = 1120 ± 227 ng*h/mL) and with a favorable terminal i.v. half-life of 1.7 ± 0.2 h. Intravenous clearance (36 ± 3 mL/min/kg) and volume of distribution (5.2 ± 0.4 L/kg) were high. The observed absolute oral bioavailability (% F) was 83 ± 14%. Given the good in vitro affinity and acceptable pharmacokinetic properties in both rats and dogs, compound 17v was selected for further profiling. Rat in-vitro radioligand binding H3R Ki values for compound 17v was 9.8 nM which is close to hH3R Ki of 8.73 nM suggesting no interspecies variation in binding affinity. Compound 17v on evaluation for its selectivity towards other receptors, showed

minimal binding against over seventy target sites including

neurotransmitter related receptors, enzymes, brain/gut peptides, growth factors/hormones, ion channels, steroids, immunological factors, second messengers and prostaglandins (Caliper life sciences, data on file). Compound 17v is characterized as dihydrochloride salt which was picked up from over 10 different salts based on its better physico-chemical properties. The dihydrochloride salt is nonhygroscopic and crystalline solid (observed under cross polarized light and crystalline compounds showed birefringence) with high water solubility (730 mg/mL).


Page 23 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


In vitro intestinal bi-directional permeability and P-gp substrate liability of compound 17v was tested (at 10 µM) in presence and absence of P-gp inhibitor Verapamil using Caco-2 cell lines. Compound 17v exhibited similar permeability in basolateral to apical (B - A) direction compared with the apical to basolateral (A - B) direction. The similar permeability in both absorptive and secretory directions in Caco-2 cells with a Papp: 30.8 x 10-6 cm/sec suggests that this compound has high permeability and is not a substrate for the efflux transporter protein. Based on the high solubility and high permeability compound 17v is considered to be a BCS Class I compound. The extent of protein binding was determined in fresh plasma obtained from rat, dog and human using Rapid Equilibrium Dialysis (RED) at a concentration of 1.0 µM. The unbound fraction of compound 17v was found to be 37, 52, and 70% in rat, dog, and human plasma respectively. The unbound fraction in rat brain homogenate, an important property for CNS compounds, was also high (57%) and comparable with that of unbound fraction found in rat plasma. To understand the in vitro metabolism of compound 17v, the metabolic stability was determined in various test systems like liver microsomes (rat, dog, monkey and human) and hepatocytes (rat, dog and human). Moderate (rat, 27%; dog, 13%; monkey, 35%) to low (human, 10 µM) in pooled human liver microsomes using specific CYP isoform marker activities, indicating no interaction potential as perpetrator for compound 17v. Compound 17v was evaluated in [35S]-GTPγS binding assay29 using CHO-K1 cells expressing human H3R membranes at Eurofins Panlabs Taiwan Ltd, Peitou, Taipei, Republic of China (Taiwan). Compound 17v exhibited an IC50 of 20 nM with progressive inhibition of (R)-α-



methylhistamine (0.03 µM) induced agonist activity below the basal levels of agonism which is a characteristic feature of an inverse agonist. Thioperamide, a reported H3R inverse agonist used as positive control exhibited an IC50 of 140 nM with inhibition slightly below the basal, at its maximum tested concentration of 1 µM.

125 % R- -Methyl histamine max

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

Page 24 of 51

Thioperamide

100

Compound 17v

75 50 25 Basal activity

0 -25 -50 -75 10 -9

10 -8

10 -7 10 -6 Concentration [M]

10 -5

Figure 2. Assessment of compound 17v functional activity at human H3R. The positive control thioperamide and compound 17v were tested in duplicates at human H3R using [35S]-GTPγS binding assay.

Compound 17v was further evaluated for its functional efficacy in (R)-α-methylhistamine (RAMH) induced dipsogenia. RAMH is a selective H3 agonist which induces water drinking in the rat when administered either peripherally or centrally. Blocking of this effect by H3R antagonists is used as an in vivo surrogate measure of H3R functional activity.30 Compound 17v, at doses of 0.3, 0.5, 0.7, 1, 3 and 10 mg/kg, p.o., reversed (R)-α-methylhistamine induced dipsogenia (Figure 3) demonstrating it to be a H3R functional antagonist. The efficacy is consistent with in-vitro potency and high CNS penetration of compound 17v. Pitolisant at the


Page 25 of 51

tested doses reversed (R)-α-methylhistamine induced dipsogenia (Figure 3) consistent with the effects of 17v. Vehicle 1 mL/kg, p.o.+ Vehicle 1 mL/kg, s.c. Vehicle 1 mL/kg, p.o.+ R--Methyl histamine 2.5 mg/kg, s.c. Compound 17v 0.3 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Compound 17v 0.5 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Compound 17v 0.7 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Compound 17v 1 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Compound 17v 3 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Compound 17v 10 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Pitolisant 1 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Pitolisant 3 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. Pitolisant 10 mg/kg, p.o + R-Methyl histamine 2.5 mg/kg, s.c. 7.5 Water intake (mL)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


5.0

2.5

0.0

** ****

****

* ****

**** ****

Treatment

Figure 3. Blockade of (R)-α-methylhistamine induced water drinking by compound 17v and Pitolisant in rats. Data represents mean ± SEM of water intake. *p 10 µM. Compound 17v, administered orally to male dogs at doses of 10, 18, and 25 mg/kg did not result in any effects on body weight, body temperature, blood pressure, heart rate, or the ECG at doses up to 25 mg/kg. Compound 17v did not have any effect on latency to fall at doses of 30 and 100 mg/kg, p.o. when assessed using rotarod test. Thus, compound 17v does not show any effect on motor coordination in animal models. Compound 17v was evaluated for CNS safety using modified Irwin’s test and found to be safe up to the highest tested dose of 100 mg/kg p.o. Compound 17v also evaluated for respiratory safety in rats at doses of 10, 30, and 90 mg/kg p.o., it did not produced no adverse effects in rats at doses up to 90 mg/kg. Compound 17v is non-mutagenic in all four strains of Salmonella typhimurium, viz., TA1537, TA1535, TA98, and TA100, and Escherichia coli WP2 uvrA both in the absence and presence of metabolic activation. It is nonclastogenic in in vitro chromosomal aberration tests in human peripheral blood lymphocytes or in vivo micronucleus assay in mice bone marrow. Compound 17v (SUVN-G3031) as a clinical candidate has successfully completed regulatory toxicology studies in rats and dogs with excellent safety margins which supported its progression to first in human studies. Phase-1 studies including pharmacokinetics, safety and tolerability


Page 28 of 51

Page 29 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


studies (ClinicalTrials.gov Identifier: NCT02342041 and NCT02881294) have been successfully completed under US IND. Compound 17v showed a favorable safety and pharmacokinetic profile in a single ascending dose in healthy male and female subjects and multiple ascending doses for 14 days in healthy male subjects. Gender, age and food did not have any significant effect on the pharmacokinetics of compound 17v. It was well tolerated in humans with adequate plasma exposures for efficacy and favorable half-life. Long term animal toxicity studies to support chronic exposures have also been completed. The complete preclinical pharmacological characterization of 17v demonstrating its potential in the treatment of sleep and cognitive disorders and the phase-1 clinical data will be published elsewhere. CONCLUSION In summary, the lactam derivative, Compound I which exhibited delayed absorption, longer half-life and poor brain penetration was modified by lactam ring opening which resulted in identification of a benzamide Series A with suboptimal PK properties and poor brain penetration. Transposing the amide in benzamide gave acetamide series B where extensive modifications like introducing the polar substituents, changing the linker and modifications in eastern, western and central domain were carried out based on the histamine H3R affinity and calculated physicochemical properties with emphasis on the duration of action of the compound in rat pharmacokinetic study and phospolipidosis inducing potential. The exhaustive work resulted in the identification of an optimal series represented by the lead compound N-[4-(1-cyclobutylpiperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride (17v, SUVN-G3031). It selectively binds to human and rat H3R with Ki values of 8.73 nM and 9.8 nM respectively, suggesting no species difference in binding affinity at H3R. Compound 17v showed selectivity at 1 µM towards panel of 70 targets comprising histamine receptors, GPCRs, ion channels,



transporters, second messengers, prostaglandins, brain/gut peptides, enzymes, kinases, and others. Compound 17v is a nonhygroscopic and crystalline dihydrochloride salt with excellent water solubility (730 mg/mL) and permeability (BCS Class I category). Compound 17v is rapidly absorbed, orally bioavailable, shorter acting brain penetrant H3R inverse agonist. Dipsogenia induced by H3 agonist (R)-α-methylhistamine was antagonized by compound 17v in rats suggesting its functional antagonism at H3R. It demonstrated high receptor occupancy (ED80 = 3.05 mg/kg). It has marked wake promoting effect with decrease in REM sleep in orexin-B lesioned rats at 10 and 30 mg/kg oral dose. It had no effect on the locomotor activity up to tested 100 mg/kg, p.o. in open field assay. Compound 17v showed negligible interactions with the hERG channel (IC50 = >10 µM) and did not show phospholipidosis inducing potential. Acceptable ADME, efficacy and safety profile supported its progression to clinical phase. The phase-1 clinical evaluation of safety and pharmacokinetics, and long term toxicity studies has been completed. The complete biological characterization of compound 17v in potential treatment of sleep and cognitive disorders will be reported in forthcoming biology publications. EXPERIMENTAL SECTION General Procedures. Unless stated otherwise, all reagents and solvents were purchased from common commercial suppliers and were used without further purification. 1H NMR spectra were recorded at 400 MHz, and 13C NMR were recorded at 100 MHz on a Bruker NMR spectrometer instrument. All 1H NMR shifts are reported in  units (ppm) relative to the signals for chloroform (7.27 ppm), DMSO (2.50 ppm), and MeOH (3.31 ppm). All coupling constants (J values) are reported in hertz (Hz). NMR abbreviations are as follows: bs, broadened singlet; s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and dd, doublet of doublets. Thin-layer chromatography (TLC) was performed on Merck silica-gel 60 F254 plates. Electrospray-


Page 30 of 51

Page 31 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


ionization mass spectra were recorded on an API 4000 triple quadrupole instrument (MDSSCIEX). Infrared spectra were recorded on KBr discs and in solid state using a PerkinElmer model 1600 FT-IR spectrophotometer (PerkinElmer). DSC was recorded on a Waters DSC Q100 instrument. Column chromatography was performed using a 100−200 mesh silica gel. The purity of all final compounds (≥95 %) was established using an Agilent 1100 high-performance liquid chromatography (HPLC) system. The chromatographic conditions are:XBridge C18 column, 150 mm × 4.6 mm, S-5 μm, detection at 250 nm, with a UV−visible detector; flow rate,1 mL/min; oven temperature, 30 °C; gradient elution with a run time of 40 min using acetonitrile-buffer (buffer: In 1000 mL ultrapure type-1 water 3.15 g (50.0 mM) of ammonium formate was added. The solution pH was adjusted to 9.0 by addition of ammonia solution). Methyl 4-(1-tert butyloxycarbonylpiperidin-4-yloxy) benzoate (3). To a stirred suspension of 1 (1.52 g, 10 mmol) and K2CO3 (2.76 g, 20 mmol) in DMF (25 mL), was added 1-tert butyloxycarbonyl-4-(tosyloxy) piperidine 2 (4.26 g, 12 mmol) at room temperature (rt). The mixture heated to 110 – 120 ºC for 6 h. The reaction mixture poured onto water (100 mL) and extracted with EtOAc (50 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated. The residue was purified by column chromatography (silica gel, hexanes: EtOAc, gradient 10-20% EtOAc) to give 3 (2.4 g, 72% yield). 1H NMR (400 MHz, CDCl3)  7.99 - 7.97 (d, J = 8.4 Hz, 2H), 6.93 - 6.91 (d, J = 8.8 Hz, 2H), 4.57 - 4.54 (m, 1H), 3.89 (s, 3H), 3.70 - 3.39 (m, 2H), 3.37 - 3.35 (m, 2H), 1.93 - 1.78 (m, 2H), 1.55 - 1.48 (m, 2H), 1.26 (s, 9H). MS-ESI (m/z): 336.2 [M+H]+. 4-(1-tert butyloxycarbonylpiperidin-4-yloxy) benzoic acid (4). To a stirred mixture of 3 (2.3 g, 6.8 mmol) in THF:H2O, was added LiOH.H2O (0.43 g, 10.3 mmol) and stirred at rt for 6 h. The mixture was concentrated, diluted with water, acidified with dil. HCl and extracted with



EtOAc (50 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporatedto give 4 (1.9 g, 85% yield). 1H NMR (400 MHz, CDCl3)  11.5 (bs, 1H), 7.99 - 7.97 (d, J = 8.8 Hz, 2H), 6.93 - 6.90 (d, J = 8.8 Hz, 2H), 4.57 4.55 (m, 1H), 3.73 - 3.66 (m, 2H), 3.40 - 3.37 (m, 2H), 1.96 - 1.91 (m, 2H), 1.79 - 1.75 (m, 2H), 1.47 (s, 9H). MS-ESI (m/z): 322.4 [M+H]+. N-[4-(1-tert butyloxycarbonylpiperidin-4-yloxy)] (2-morpholin-4-yl ethyl) benzamide (6b). To a stirred solution of 4 (0.65 g, 2.02 mmol), 4-(2-aminoethyl)morpholine (5b, 0.29 g, 2.22 mmol) and triethyl amine (0.7 mL, 5.06 mmol) in DCM (25 mL) was added (benzotriazol1-yloxy)tripyrrolidinophosphoniumhexafluorophosphate (PyBop, 1.26 g, 2.4 mmol). The mixture was stirred at rt for 15 h. The mixture was washed with water (25 mL), separated organic layer, dried over anhydrous Na2SO4, filtered and evaporated. The residue was purified by column chromatography (silica gel, EtOAc:Methanol, gradient 5% methanol) to give 6b (0.64 g, 73% yield). 1H NMR (400 MHz, CDCl3)  7.78 (m, 2H), 7.04 (bs, 1H), 6.96 - 6.94 (d, J = 8.0 Hz, 2H), 4.54 (m, 1H), 3.82 (m, 4H), 3.69 - 3.62 (m, 4H), 3.36 (m, 2H), 3.17 (m, 2H), 2.75 (m, 2H), 1.93 (m, 2H), 1.82 (m, 4H), 1.48 (s, 9H). MS-ESI (m/z): 434.4 [M+H]+. N-[(2-Morpholin-4-yl ethyl)]-4-(piperidin-4-yloxy) benzamide dihydrochloride (7b). To a stirred solution of 6b (0.6 g, 1.38 mmol) in isopropyl alcohol (5 mL) was added IPA.HCl (5 mL, 16% w/v solution). The mixture was refluxed for 2 h. The mixture was evaporated to give 7b (0.54 g, 90% yield). 1H NMR (400 MHz, DMSO-d6)  10.91 (bs, 1H), 8.96 (bs, 2H), 8.80 (bs, 1H), 7.92 - 7.90 (d, J = 8.8 Hz, 2H), 7.08 - 7.06 (d, J = 8.4 Hz, 2H), 4.75 (m, 1H), 3.97 (m, 2H), 3.84 - 3.78 ( m, 2H), 3.67 - 3.65 (m, 2H), 3.28 - 3.16 (m, 4H), 3.10 - 3.07 (m, 4H), 3.06 - 3.00 (m, 2H), 2.10 (m, 2H), 1.84 - 1.82 (m, 2H). MS-ESI (m/z): 334.1 [M+H]+.


Page 32 of 51

Page 33 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


N-[4-(1-Cyclobutylpiperidin-4-yloxy)] (2-morpholin-4-yl ethyl) benzamide (9b).

To a

stirred mixture of 7b (0.25 g, 0.61 mmol), 8b (64 mg, 0.92 mmol), and triethyl amine (0.25 mL, 1.84 mmol) in 1,2-dichloroethane (10 mL) was added sodium triacetoxyborohydride (0.26 g, 1.23 mmol). The mixture was stirrred at rt for 16 h and then poured into water (25 mL), basified with 1N NaOH solution and extracted with DCM (30 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporatedto give 9b (0.19 g, 82% yield). 1H NMR (400 MHz, CDCl3)  7.73 - 7.71 (d, J = 8.4 Hz, 2H), 6.94 - 6.92 (d, J = 8.4 Hz, 2H), 6.64 (s, 1H), 4.42 - 4.39 (m, 1H), 3.74 - 3.72 (m, 4H), 3.55 - 3.52 (m, 2H), 3.17 - 3.15 (m, 2H), 2.77 - 2.73 (m, 1H), 2.61 - 2.58 (m, 4H), 2.52 - 2.17 (m, 4H), 2.08 - 2.04 (m, 2H), 2.02 - 1.92 (m, 4H), 1.87 - 1.83 (m, 2H), 1.73 - 1.69 (m, 2H). MS-ESI (m/z): 388.5 [M+H]+. 1-Cyclobutylpiperidin-4-ol (11b).To a stirred solution piperidin-4-ol (10, 10.1 g, 100 mmol) in ethylene dichloride (200 mL), was added cyclobutanone (8b, 8.4 g, 120 mmol). The mixture stirred at rt for 90 min. Sodium triacetoxyborohydride (42.4 g, 200 mmol) was added in portions to the above solution at rt and stirred for further 18 h at same temperature. The mixture was added to water (250 mL), basified with 1N NaOH solution and separated organic layer. The aqueous layer was again extracted with DCM (100 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporatedto give 11b (14.5 g, 95% yield). 1H NMR (400 MHz, CDCl3)  3.66 - 3.70 (m, 1H), 2.69 - 2.65 (m, 3H), 2.02 - 1.83 (m, 8H), 1.69 - 1.55 (m, 5H). MS-ESI (m/z): 156.2 [M+H]+. 4-(1-Cyclobutylpiperidin-4-yloxy)-1-nitrobenzene (13b). To a stirred suspension of sodium hydride (19.3 g, 483 mmol, 60% suspension in mineral oil) in THF (100 mL) at 35-40 °C, was added, a solution of 11b (50 g, 322 mmol) in THF (150 mL) and maintained for 90 minutes at



same temperature. A solution of 12a (54.5 g, 386 mmol) in THF (120 mL) was added to the above mixture at 35-40 ºC and stirred for 4 h. The mixture was added to water (2 L) under stirring during which yellow solids precipitated out. These solids were filtered, washed with water (200 mL x 3) and dried to obtain a wet solid cake. Purification: The above wet cake was dissolved in 10% acetic acid solution (10 vol.), and washed with toluene (150 mL x 3). The aqueos layer was separated and the pH was adjusted to 11.5 – 12 with 20% aqueous NaOH solution at 10-15 ºC. The mixture was further stirred for 15 min and the yellow solids precipitated during basification were filtered. The solid cake was washed with water (100 mL x 2) and dried to give 13b (69.5 g, 78% yield). 1H NMR (400 MHz, CDCl3)  8.20 - 8.18 (d, J = 9.0 Hz, 2H), 6.95 - 6.93 (d, J = 9.1 Hz, 2H), 4.45 (s, 1H), 2.76 - 2.71 (m, 1H), 2.62 (s, 2H), 2.19 (s, 2H), 2.06 - 2.02 (m, 4H), 1.93 - 1.84 (m, 4H), 1.73 - 1.58 (m, 2H). MS-ESI (m/z): 277.2 [M+H]+. 13C NMR (100 MHz, CDCl3):  162.7, 141.09, 125.87, 115.22, 60.14, 46.4, 30.07, 27.3, 14.04. 4-(1-Cyclobutylpiperidin-4-yloxy) aniline (14b). A mixture of Fe powder (47.1 g, 844 mmol), NH4Cl (52 g, 970 mmol) and water (150 mL) was refluxed for 90 min. A solution of 13b (58.3 g, 211 mmol) in ethyl alcohol (DS, 590 mL) was added to the above mixture at 70 ºC and refluxed for 3 h and the mixture was filtered through hyflow. The filtrate was concentrated to obtain a residue. The residue was diluted with water (180 mL) and pH was adjusted to 9-10 with sodium carbonate solution (~40% solution) and the mixture was extracted with EtOAc (500 mL). The organic layer was separated, filtered through hyflow, dried over anhydrous Na2SO4 and evaporated to give 14b (44.8 g, 86.3 % yield). 1H NMR (400 MHz, DMSO-d6)  6.63 - 6.61 (d, J = 8.4 Hz, 2H), 6.47 - 6.45 (d, J = 8.5 Hz, 2H), 4.60 (2H, s), 4.01 - 3.99 (m, 1H), 2.68 - 2.60 (m,


Page 34 of 51

Page 35 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


1H), 2.53 - 2.49 (m, 2H), 1.97 - 1.92 (m, 4H), 1.82 - 1.69 (m, 4H), 1.61 - 1.46 (m, 4H). MS-ESI (m/z): 247.3 [M+H]+. 2-Chloro-N-[4-(1-cyclobutylpiperidin-4-yloxy) phenyl] acetamide (15b). To a stirred suspension of 14b (44 g, 0.178 mmol) and K2CO3 powder (49.3 g, 357 mmol) in THF (360 mL) at 10 to 5 ºC, was added, a solution of chloroacetylchloride (26.3 g, 232 mmol) in THF (180 mL) and further stirred at same temperature for 2 h. The mixture was added to water (150 mL) and extracted using EtOAc (150 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporatedto give 15b (56.6 g, 98% yield). 1H

NMR (400 MHz, DMSO-d6)  10.1 (s, 1H), 7.46 - 7.44 (d, J = 8.8 Hz, 2H), 6.90 - 6.88 (d, J =

8.8 Hz, 2H), 4.28 - 4.24 (m, 1H), 4.19 (s, 2H), 2.70 - 2.62 (m, 1H), 2.54 - 2.48 (m, 2H), 2.01 1.86 (m, 6H), 1.76 - 1.72 (m, 2H), 1.62 - 1.50 (m, 4H). MS-ESI (m/z): 323.2, 325.2 [M+H]+. N-[4-(1-Cyclobutylpiperidin-4-yloxy)-2-methylphenyl]-2-(piperidin-1-yl)

acetamide

dihydrochloride (17n). To a stirred solution of 23a (0.5 g, 1.51 mmol), and acetic acid (0.09 g, 1.51 mmol) in 1,2-dichloroethane (10 mL) was added 8b (0.13 g, 1.81 mmol) at room temperature, and the reaction mixture was stirred for 3 h at the same temperature. Sodium triacetoxyborohydride (0.64 g, 3.02 mmol) was added to above mixture and stirred for 15 h. The mixture was diluted with water (50 mL), basified with 1N NaOH solution and extracted with DCM (25 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated. The residue was purified by column chromatography (silica gel, EtOAc:Methanol, gradient 1-2% methanol) to give 17n (0.44 g, 76% yield). 1H NMR (400 MHz, CDCl3)  9.26 (s, 1H), 7.91 - 7.89 (d, J = 9.2 Hz, 1H), 6.77 - 6.75 (m, 2H), 4.28 (bs, 1H), 3.10 - 3.12 (m, 2H), 2.75 - 2.73 (m, 1H), 2.57 - 2.59 (m, 6H), 2.26 - 2.23 (m, 5H), 2.01 1.91 (m, 6H), 1.83 - 1.61 (m, 8H), 1.50 - 1.49 (m, 2H). MS-ESI (m/z): 386.3 [M+H]+. HCl Salt



Page 36 of 51

formation: To a stirred solution of above compound in methanol (10 mL) at rt, added methanolic HCl (16 % w/v solution, 2.85 mmol) and the mixture was stirred at same temperature for 2 h. The mixture was evaporated and the resulting mass was triturated with ether and dried to give 17n as hydrochloride salt (0.48 g, 92% yield). 1H NMR (400 MHz, DMSO-d6)  11.05 (bs, 1H), 10.07 - 10.05 (d, J = 8.0 Hz, 1H), 9.83 (bs, 1H), 7.26 - 7.22 (t, J = 8.2 Hz, 1H), 6.93 - 6.88 (m, 2H), 4.52 (m, 1H), 3.40 - 3.35 (m, 2H), 3.15 (s, 2H), 3.07 - 3.02 (m, 2H), 2.90 - 2.81 (m, 1H), 2.36 - 2.35 (m, 2H), 2.17 (s, 3H), 2.15 - 2.09 (m, 4H), 1.98 - 1.92 (m, 2H), 1.89 - 1.77 (m, 4H), 1.73 -1.68 (m, 4H), 1.40 (m, 2H). MS-ESI (m/z): 386.2 [M+H]+. N-[4-(1-Cyclobutylpiperidin-4-yloxy)

phenyl]-2-(morpholin-4-yl)

acetamide

dihydrochloride (17v). To a stirred solution of 15b (10 g, 309 mmol) and methanol (100 mL), was added 16n (6.72 g, 774 mmol) and refluxed for 4 h. The mixture was concentrated to obtain solids. These solids were diluted with water (100 mL), neutralized with aqueous 20% Na2CO3, the resulting solids were filtered. The solid cake was dissolved in ethyl acetate (150 mL), washed with water (75 mL), brine (75 mL), dried over anhydrous Na2SO4 and evaporated to give free base of 17v (10.4 g, 90% yield). 1H NMR (400 MHz, DMSO-d6)  9.55 (s, 1H), 7.49 - 7.47 (d, J = 8.7 Hz, 2H), 6.87 - 6.85 (d, J = 8.8 Hz, 2H), 4.27 - 4.23 (m, 1H), 3.62 - 3.60 (t, J = 4.4 Hz, 4H), 3.06 (s, 2H), 2.68 - 2.62 (m, 1H), 2.54 - 2.47 (m, 6H), 1.99 - 1.56 (m, 6H), 1.76 - 1.72 (m, 2H), 1.61 - 1.52 (m, 4H). MS-ESI (m/z): 374.4 [M+H]+. To a stirred solution of free base of 17v (5 g, 133 mmol) in isopropyl alcohol (50 mL), was added IPA.HCl (6.7 mL, 18% w/v solution) diluted with IPA (5 mL) at rt during which solids precipitated out. The mixture was further stirred at rt for 2 h, filtered the solids and the solid cake was washed with IPA (10 mL x 2) and sucked dry to give the dihydrochloride salt 5.4 g, 90.7% yield. Recrystallization: To a stirred solution of above dihydrochloride salt in methanol (25


Page 37 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


mL), was added IPA (25 mL) at 60-62 ºC and maintained at same temperature for 30 min. The mixture was allowed to cool to rt during which solids precipitated out. The mixture was further stirred at 15-20 ºC for 2 h, filtered the solids, washed with IPA (10 mL x 2) and dried in oven to give 17v (3.8 g, 70% yield). 1H NMR (400 MHz, DMSO-d6)  11.18 (bs, 1H), 10.79 (bs, 1H), 10.61 (bs, 1H), 7.55 - 7.51 (m, 2H), 7.02 - 6.96 (m, 2H), 4.70 - 4.48 (m, 1H), 4.16 (bs, 2H), 3.90 - 3.67 (m, 6H), 3.19 - 3.16 (m, 5H), 2.89 - 2.78 (m, 2H), 2.40 - 2.35 (m, 2H), 2.14 (bs, 4H), 2.00 - 1.93 (m, 2H), 1.74 - 1.63 (m, 2H). 13C-NMR (100 MHz, DMSO-d6) δ 13.61, 13.74, 25.07, 25.24, 26.13, 28.03, 44.00, 47.20, 52.16, 57.26, 58.30, 63.52, 67.46, 71.37, 116.49, 117.21, 121.52, 132.14, 132.36, 153.18, 153.54, 162.57. MS-ESI (m/z): 374.4 [M+H]+. DSC (5 ºC / min, onset): 263.14 ºC. IR (cm-1): 3443, 3281, 3137, 2932, 2499, 1686, 1602, 1551, 1509, 1241, 1120, 831. 4-[(1-tert butyloxycarbonyl piperidin-4-yloxy)-2-methyl]-1-nitrobenzene (19a). To a stirred suspension of 18a (1 g, 6.53 mmol) and K2CO3 (1.35 g, 9.8 mmol) in DMF (10 mL) was added 2 (2.55 g, 7.18 mmol). The mixture was stirred at 110 ºC for 3 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (100 mL x 2). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated. The residue was purified by column chromatography (silica gel, hexanes: EtOAc, gradient 5-10% EtOAc) to give 19a (1.86 g, 85% yield). 1H NMR (400 MHz, CDCl3)  8.09 - 8.07 (d, J = 9.6 Hz, 1H), 6.80 - 6.79 (d, J = 7.6 Hz, 2H), 4.59 - 4.57 (m, 1H), 3.72 - 3.66 (m, 2H), 3.41 - 3.35 (m, 2H), 2.63 (s, 3H), 1.97 - 1.92 (m, 2H), 1.80 - 1.75 (m, 2H), 1.48 (s, 9H). MS-ESI (m/z): 337.4 [M+H]+. 4-[(1-tert butyloxycarbonyl piperidin-4-yloxy)-2-methyl] aniline (20a). Compound 20a was prepared from 19a in a manner similar to that of 14b in 1.56 g, 87% yield. 1H NMR (400 MHz, CDCl3)  6.69 - 6.67 (m, 1H), 6.66 - 6.61 (m, 2H), 4.28 - 4.26 (m, 1H), 3.74 - 3.68 ( m, 2H), 3.49



Page 38 of 51

(s, 2H), 3.30 - 3.24 (m, 2H), 2.16 (m, 3H), 1.86 - 1.85 (m, 2H), 1.72 - 1.68 (m, 2H), 1.47 (s, 9H). MS-ESI (m/z): 307.1 [M+H]+. 2-Chloro-N-[4-(1-tert butyloxycarbonyl piperidin-4-yloxy)-2-methyl phenyl] acetamide (21a). Compound 21a was prepared from 20a in a manner similar to that of 15b in 1.13 g, 91% yield. MS-ESI (m/z): 382.5, 384.1 [M+H]+. N-[4-(1-tert

butyloxycarbonylpiperidin-4-yloxy)-2-methyl

phenyl]-2-(piperidin-1-yl)

acetamide (22c). To a stirred suspension of 21a (0.9 g, 2.35 mmol) and K2CO3 (0.48 g, 3.5 mmol) in DMF (10 mL) was added 16e (0.24 g, 2.82 mmol). The mixture was stirred at 75 ºC for 3 h. The mixture was diluted with water (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated. The residue was purified by column chromatography (silica gel, hexanes: EtOAc, gradient 20-25% EtOAc) to give 22c (0.87 g, 78% yield). MS-ESI (m/z): 432.6 [M+H]+. N-[4-(Piperidin-4-yloxy)-2-methyl phenyl]-2-(piperidin-1-yl) acetamide (23c). To a stirred solution of 22c (0.8 g, 1.85 mmol) in methanol (10 mL) was added methanolic HCl (16%w/v solution, 18.5 mmol). The solution was stirred at rt for 3 h and concentrated to get syrupy mass. This mass was diluted with water (10 mL), basified with 1 N NaOH and extracted with EtOAc (10 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated to 23c (0.52 g, 85% yield). MS-ESI (m/z): 332.2 [M+H]+. N-[4-(Piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide (23j). 1H NMR (400 MHz, CDCl3)  8.93 (s, 1H), 7.47 - 7.45 (d, J = 8.8 Hz, 2H), 6.90 - 6.88 (d, J = 8.8 Hz, 2H), 4.34 - 4.32


Page 39 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


(m, 1H), 3.79 - 3.76 (m, 4H), 3.16 (s, 3H), 2.77 - 2.71 (m, 2H), 2.63 - 2.61 (m, 4H), 2.03 - 1.99 (m, 2H), 1.86 - 1.70 (m, 2H), 1.71 - 1.65 (m, 2H). MS-ESI (m/z): 320.6 [M+H]+. 2-Chloro-N-(4-morpholin-4-yl-phenyl) acetamide (25a). Compound 25a was prepared from 24a in a manner similar to that of 15b in0.66 g, 73% yield. 1H NMR (400 MHz, CDCl3 )  8.15 (bs, 1H), 7.45 - 7.43 (d, J = 8.8 Hz, 2H), 6.91 - 6.89 (d, J = 8.9 Hz, 2H), 4.18 (s, 2H), 3.87 - 3.85 (m, 4H), 3.15 - 3.12 (m, 4H). MS-ESI (m/z): 255.3, 257.3 [M+H]+. 2-(2(R)-Methyl-pyrrolidin-1-yl)-N-(4-morpholin-4-yl-phenyl) acetamide (26a). Compound 26a was prepared by the reaction of 25a with 16d in a manner similar to that of 17v in 0.31 g, 90% yield. 1H NMR (400 MHz, CDCl3) . 9.10 (bs, 1H), 7.49 - 7.47 (d, J = 8.8 Hz, 2H), 6.91 6.89 (d, J = 8.8 Hz, 2H), 3.88 - 3.85 (m, 4H), 3.43 - 3.39 (m, 2H), 3.21 - 3.10 (m, 4H), 2.62 2.60 (m, 1H), 2.03 - 1.98 (m, 2H), 1.86 - 1.78 (m, 2H), 1.50 - 1.48 (m, 2H), 1.13 - 1.11 (d, 3H). MS-ESI (m/z): 304.6 [M+H]+. N-[4-(1-Cyclobutylpiperidin-4-yloxy)

phenyl]-N-methyl-2-(morpholin-4-yl)

acetamide

(27a). To a stirred mixture of 17v (0.5 g, 1.34 mmol) and NaH (80 mg, 60% suspension in mineral oil, 2.01 mmol) in DMF (5 mL), was added CH3I (0.23 g, 1.60 mmol) at rt. The mixture stirred at 65-70 ºC for 4 h. The mixture was then poured onto water (25 mL), extracted with EtOAc (25 mL x 3). The combined organic extracts were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and evaporated. The residue was purified by column chromatography (silica gel, EtOAc:MeOH, gradient 5-10% MeOH) to give 27a (0.16 g, 32% yield). 1H NMR (400 MHz, CDCl3) 7.10 - 7.08 (m, 2H), 6.92 - 6.90 (d, J = 8.0 Hz, 2H), 4.34 - 4.30 (m, 1H), 3.70 - 3.68 (m, 4H), 3.22 (s, 3H), 2.90 (s, 2H), 2.84 - 2.75 (m, 2H), 2.65 - 2.63 (m, 2H), 2.40 2.38 (m, 3H), 2.21 - 2.19 (m, 2H), 2.05 - 2.02 (m, 7H), 1.74 - 1.67 (m, 3H). MS-ESI (m/z): 388.6 [M+H]+.



N-[2-(1-Cyclobutylpiperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide (28). 1H NMR (400 MHz, DMSO-d6)  9.64 (bs, 1H), 8.30 - 8.28 (d, J = 7.2 Hz, 1H), 7.11 - 7.10 (d, J = 7.2 Hz, 1H), 7.03 - 7.00 (t, J = 7.2 Hz, 1H), 6.93 - 6.89 (t, J = 7.2 Hz ,1H), 4.48 (bs, 1H), 3.67 (s, 4H), 3.14 (s, 2H), 2.66 - 2.66 (m, 1H), 2.58 (m, 4H), 2.00 - 1.99 (m, 8H), 1.78 - 1.65 (m, 6H). Mass (m/z): 374.2 [M+H]+. N-[3-(1-Cyclobutylpiperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide (29). 1H NMR (400 MHz, CDCl3)  9.65 (s, 1H), 8.15 - 8.13 (t, J = 8.0 Hz, 1H), 7.62 - 7.52 (m, 2H), 7.39 - 7.37 (dd, J = 8.8, 2.4 Hz, 1H), 4.35 - 4.32 (m, 1H), 3.78 - 3.76 (m, 4H), 3.15 (s, 2H), 2.78 - 2.74 (m, 1H), 2.65 - 2.63 (m, 6H), 2.20 - 2.15 (m, 2H), 2.08 - 1.97 (m, 4H), 1.92 - 1.80 (m, 4H), 1.73 1.66 (m, 2H). MS-ESI (m/z): 374.3 [M+H]+. Animals and Ethics. All animal care and experiments were carried out according to protocols approved by the Institutional Animal Ethics Committee (IAEC) of Suven Life Science Ltd., constituted according to the directions of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), India. Determination of Ki value at human histamine H3 receptor: The histamine H3 radioligand binding assay was performed according to the published procedure.38 Histamine H3 membranes were prepared from recombinant CHO-K1 cells expressing human or rat histamine H3R, Radioligand (RS)-α-Methylhistamine [ring-1,2-3H] was purchased from American Radiolabeled chemicals (ARC) (Cat No. ART 1342). The final ligand concentration was 3 nM; non-specific determinant was Methyl histamine (100 µM) and H3 membrane (60 µg/well). Methyl histamine was used as a positive control. Reactions were carried out in binding buffer 50 mM Tris-HCl (pH 7.4) buffer containing 5 mM MgCl2 for 60 minutes at 25 ºC. Incubation was stopped by rapid filtration followed by four washes of the binding mixture using 96 well harvest plate (Millipore


Page 40 of 51

Page 41 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Cat no. MSFCNXB50) pre coated with 0.5% polyethyleneimine. The plate was dried and the bound radioactivity collected on the filters was determined by scintillation counting using MicroBetaTriLux. Radio ligand binding in the presence of non labeled compound was expressed as a percent of the total binding and plotted against the log concentration of the compound. Ki values were determined using GraphPad Prism 4 (GraphPad Software, La Jolla, CA, USA) data analysis software package and curve-fitting program. Under these tested assay conditions for human and rat H3R, Ki value obtained for reference compound Methyl histamine is 3.45 nM and 2.62 nM respectively. Electroencephalography (EEG) in Orexin-B-SAP lesioned rats: Rats were anesthetized with isoflurane (Baxter India Private Limited; 4% in oxygen for induction; 2% for maintenance) and were fixed into the stereotaxic frame (Stoelting, Illinois, USA) to perform surgery. An incision was made to reveal bregma from which coordinates were taken. Telemetric transmitter (Model F40-EET; DSI, St. Paul, MN, USA) was implanted into intraperitoneal cavity of the rat and leads were tunneled subcutaneously to head. One pair of electrodes were implanted epidurally into the frontal cortex region using stainless steel screws (CMA Microdialysis, Stockholm, Sweden) at coordinates39 of AP +2.0 mm, ML ±2.2 mm for recording of EEG and electrodes were fixed to the skull with dental acrylic cement (DENTALON® plus). The second set of lead wires was implanted into the neck nuchal muscle to record electromyogram (EMG).After the implantation of electrodes, orexin-B-SAP conjugate (490 ng/0.8 µl; Advanced Targeting Systems) were made bilaterally to the lateral hypothalamus using a micro-injector (Make- Harvard apparatus, Holliston, MA, USA) using airtight glass syringe with glass needle. After injection the needle was left in place for 5-6 min and then was withdrawn slowly. The coordinates for lateral hypothalamus were AP: -3.5 mm; ML: ± 1.5 mm from bregma and DV: -



8.7 mm from dura35. Incision was closed using non absorbable sutures. After a surgical recovery of minimum 3 weeks, animals were acclimatized to the handling procedures and were given a mock dosing for 3 days before the first experimental day. On the day of study, transmitter was switched on using magnet and animals were transferred on to the receiver along with the home cage. Recording was started approximately 0.5 h before the lights-off using Ponemah (Version 5.2) software. Animals were treated 15 min before lights-off with vehicle or Compound 17v in a cross-over design with washout period of one week between doses. Recording was continued overnight. EEG and EMG were collected as primary signals and sampled at 500 Hz. whereas, temperature and activity were sampled at 250 Hz. The data was stored for off-line analysis using NeuroScore software (Version 3.0).Wakefulness was identified by the presence of desynchronized EEG and high EMG activity. Non-rapid eye movement sleep (NREM) consisted of high-amplitude slow waves together with a low EMG tone relative to waking. REM sleep was identified by the presence of desynchronized EEG and/or activity coupled with low EMG relative to NREM sleep. The amount of time spent in wake, NREM, and REM sleep was determined for every 30 min. Data is represented as total time spent in Wake, REM and NREM sleep during 3 h post-treatment of vehicle or compound 17v and statistical significance between the groups was evaluated separately for wake, REM and NREM using Dunnett’s multiple comparison test (GraphPad Prism). Additionally numbers of direct REM sleep onset (DREM) episodes were identified as transition to REM after minimum 60 s of wake period. Numbers of DREM episodes after treatment with compound 17v were compared against vehicle using Dunnett’s multiple comparison test (GraphPad Prism). ASSOCIATED CONTENT Supporting Information


Page 42 of 51

Page 43 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


The Supporting Information is available free of charge on the ACS Publications website at DOI: Determination of Ionization constants (pKa), Determination of LogP and LogD Values, Pharmacokinetic Study in Rats, Rodent Brain Penetration Study, hERG Patch clamp Assay IC50 determination, Phospholipidosis screening assay, Microsomal metabolic stability, CYP 3A4 and 2D6 inhibition , Pharmacokinetic Study in Dogs, (R)-α-methylhistamine induced dipsogenia assay in Rats, [35S]-GTPγS binding assay, Determination of in vivo receptor occupancy in male wistar rats, Compound characterization data for other all remaining compounds, and Analytical data reports. Molecular-formula strings (CSV) ■ AUTHOR INFORMATION Corresponding Author *E-mail: [email protected]. ORCID Ramakrishna Nirogi: 0000-0002-2045-0784 Notes The authors declare no competing financial interest. ACKNOWLEDGMENTS



Page 44 of 51

The support of scientists from Discovery research, Suven Life Sciences Ltd., and moral and financial support from Venkateswarlu Jasti, CEO, Suven Life Sciences Ltd., Hyderabad, are greatly acknowledged. ■ ABBREVIATIONS USED H3R, Histamine 3 receptor; GPCR, G-protein-coupled receptor; EMA, European Medicines Agency; Ki, inhibition constant; EEG, Electroencephalography; EMG, Electromyography; REM, Rapid eye movement, DREM, Direct rapid eye movement; NREM, Non-rapid eye movement sleep; RAMH, (R)-α-methylhistamine; SAR, structure−activity relationships; p.o., oral dosing; i.v., intravenous; hERG, human Ether-à-go-go-related gene; PK, pharmacokinetics; LogP, logarithm of partition coefficient; pKa, Ionization constant; Cmax, Maximum (peak) plasma drug concentration, AUC, Area under the plasma concentration-time curve, Tmax, Time to reach maximum (peak) plasma concentration following drug administration, Vdss, volume of distribution at steady state, t1/2, half-time; Cb/Cp, brain concentration/plasma concentration; RO, receptor occupancy; HPLC, high-performance liquid chromatography; HEK, human embryonic kidney; HLM, human liver microsome; RLM, rat liver microsome; DCM, dichloromethane; TLC,

thin-layer

chromatography;

mmol,

millimole;

PyBop,

(benzotriazol-1-

yloxy)tripyrrolidinophosphoniumhexafluorophosphate; IPA, isopropanol; EtOAc, ethyl acetate.


Page 45 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


REFERENCES 1. Scammell, T. E. Narcolepsy. N. Engl. J. Med. 2015, 373, 2654–2662. 2. Dauvilliers, Y.; Arnulf, I.; Mignot, E. Narcolepsy with cataplexy. Lancet 2007, 369, 499– 511. 3. Jennum, P.; Ibsen, R.; Petersen, E. R.; Knudsen, S.; Kjellberg, J. Health, social, and economic consequences of narcolepsy: A controlled national study evaluating the societal effect on patients and their partners. Sleep Med. 2012, 13, 1086–1093. 4. Black, J.; Reaven, N. L.; Funk, S. E.; McGaughey, K.; Ohayon, M.; Guilleminault, C.; Ruoff, C.; Mignot, E. The burden of narcolepsy disease (BOND) study: healthcare utilization and cost findings. Sleep Med. 2014, 15, 522–529. 5. Leurs, R.; Bakker, R. A.; Timmerman, H.; de Esch, I. J. P. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discovery 2005, 4, 107–120. 6. Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends Pharmacol. Sci. 1998, 19, 177–183. 7. Esbenshade, T. A.; Browman, K. E.; Bitner, R. S.; Strakhova, M.; Cowart, M. D.; Brioni, J. D. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br. J. Pharmacol. 2008, 154, 1166–1181. 8. Parmentier, R.; Anaclet, C.; Guhennec, C.; Brousseau, E.; Bricout, D.; Giboulot, T.; Bozyczko-Coyne, D.; Spiegel, K.; Ohtsu, H.; Williams, M.; Lin, J. S. The brain H3receptor as a novel therapeutic target for vigilance and sleep–wake disorders. Biochem. Pharmacol. 2007, 73, 1157–1171. 9. Bonaventure, P.; Letavic, M.; Dugovic, C.; Wilson, S.; Aluisio, L.; Pudiak, C.; Lord, B.; Mazur, C.; Kammea, F.; Nishino, S.; Carruthers, N.; Lovenberg, T. Histamine H3 receptor



Page 46 of 51

antagonists: from target identification to drug leads. Biochem. Pharmacol.2007, 73, 10841096. 10. Ligneau, X.; Perrin, D.; Landais, L.; Camelin, J. C.; Calmels, T. P.; Berrebi-Bertrand, I.; Lecomte, J. M.; Parmentier, R.; Anaclet, C.; Lin, J. S.; Bertaina-Anglade, V.; Drieu la Rochelle, C.; d’Aniello, F.; Rouleau, A.; Gbahou, F.; Arrang, J. M.; Ganellin, C.R.; Stark, H.;

Schunack,

W.;

Schwartz,

J.

C.

BF2.649

[1-{3-[3-(4-Chlorophenyl)

propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J. Pharmacol. Exp. Ther.2007, 320, 365-375. 11. Toyota, H.; Dugovic, C.; Koehl, M.;Laposky, A.D.; Weber, C.; Ngo, K.; Wu, Y.; Lee, D.H.; Yanai, K.; Sakurai, E.; Watanabe, T.; Liu, C.; Chen, J.; Barbier, A.J.; Turek, F.W.; Fung-Leung, W.P.; Lovenberg, T.W. Behavioral characterization of mice lacking histamine H3 receptors. Mol. Pharmacol. 2002, 62, 389–397. 12. Monti, J. M.; Jantos, H.; Boussard, M.; Altier, H.; Orellana, C.; Olivera, S. Effects of selective activation or blockade of the histamine H3 receptor on sleep and walkefulness. Eur. J. Pharmacol. 1991, 205, 283–287. 13. Lin, J. S.; Sakai, K.; Vanni-Mercier, G.; Arrang, J. M.; Garbarg, M.; Schwartz, J. C.; Jouvet, M. Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3 receptor ligands in the cat. Brain Res. 1990, 523, 325–330. 14. Boutrel, B.; Koob, G. F. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications? Sleep 2004, 27, 1181–1194. 15. Radulovacki, M.; Walovitch, R.; Yanik, G. Caffeine produces REM sleep rebound in rats. Brain Res. 1980, 201, 497-500.


Page 47 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


16. Monti, J. M.; Jantos, H.; Ponzoni, A.; Monti, D. Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996, 15, 31–35. 17. Ligneau, X.; Lin, J. S.; Vanni-Mercier, G.; Jouvet, M.; Muir, J. L.; Ganellin, C. R.; Stark, H.; Elz, S.; Schunack, W.; Schwartz, J. C. Neurochemical and behavioral effects of Ciproxifan, a potent histamine H3 receptor antagonist. J. Pharmacol. Exp. Ther. 1998, 287, 658–666. 18. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002616/ human_med_001955.jsp&mid=WC0b01ac058001d124 (accessed August 9, 2018). 19. Gao, Z.; Hurst, W. J.; Czechtizky, W.; Hall, D.; Moindrot, N.; Nagorny, R.; Pichat, P.; Stefany, D.; Hendrix, J. A.; George, P. G. Identification and profiling of 3,5-dimethylisoxazole-4-carboxylic

acid

[2-methyl-4-((2S,3'S)-2-methyl-[1,3']bipyrrolidinyl-1'-

yl)phenyl] amide as histamine H3 receptor antagonist for the treatment of depression. Bioorg. Med. Chem. Lett. 2013, 23, 6269–6273. 20. Wager, T. T.; Pettersen, B. A.; Schmidt, A. W.; Spracklin, D. K.; Mente, S.; Butler, T. W.; Howard, H.; Lettiere, D. J.; Rubitski, D. M.; Wong, D. F.; Nedza, F. M.; Nelson, F. R.; Rollema, H.; Raggon, J. W.; Aubrecht, J.; Freeman, J. K.; Marcek, J. M.; Cianfrogna, J.; Cook, K. W.; James, L. C.; Chatman, L. A.; Iredale, P. A.; Banker, M. J.; Homiski, M. L.; Munzner, J. B.; Chandrasekaran, R. Y. Discovery of two clinical histamine H3receptor antagonists:

trans-N-ethyl-3-fluoro-3-[3-fluoro-4-

(pyrrolidinylmethyl)phenyl]cyclobutanecarboxamide (PF-03654746) and trans-3-fluoro-3[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]-N-(2-ethylpropyl)cyclobutanecarboxamide (PF-03654764). J. Med. Chem. 2011, 54, 7602–7620.



21. Bernstein, P. R.; Ciaccio, P. J.; Morelli, J. K. Drug-induced phospholipidosis. Ann. Rep. Med. Chem. 2011, 46, 419–430. 22. Dvorak, C. A.; Apodaca, R.; Barbier, A. J.; Berridge, C. W.; Wilson, S. J.; Boggs, J. D.; Xiao, W.; Lovenberg, T. W.; Carruthers, N. I. 4-Phenoxypiperidines: potent, conformationally restricted, non-imidazole histamine H3 antagonists. J. Med. Chem. 2005, 48, 2229–2238. 23. Letavic, M. A.; Aluisio, L.; Apodaca, R.; Bajpai, M.; Barbier, A. J.; Bonneville, A.; Bonaventure, P.; Carruthers, N. I.; Dugovic, C.; Fraser, I. C.; Kramer, M. L.; Lord, B.; Lovenberg, T. W.; Li, L. Y.; Ly, K. S.; Mcallister, H.; Mani, N. S.; Morton, K. L.; Ndifor, A.; Nepomuceno, S. D.; Pandit, C. R.; Sands, S. B.; Shah, C. R.; Shelton, J. E.; Snook, S. S.; Swanson, D. M.; Xiao, W. Novel benzamide-based histamine H3receptor antagonists: the identification of two candidates for clinical development. ACS Med. Chem. Lett. 2015, 6, 450–454. 24. Hudkins, R. L.; Gruner, J. A.; Raddatz, R.; Mathiasen, J. R.; Aimone, L. D.; Marino, M. J.; Bacon, E. R.; Williams, M.; Ator, M. A. 3-(1′-Cyclobutylspiro[4H-1,3-benzodioxine-2,4′piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wakepromoting histamine H3 antagonist/inverse agonist. Neuropharmacology, 2016, 106, 3745. 25. Raddatz, R.; Hudkins, R. L.; Mathiasen, J. R.; Gruner, J. A.; Flood, D. G.; Aimone, L. D.; Le, S.; Schaffhauser, H.; Duzic, E. Gasior, M.; Bozyczko-Coyne, D.; Marino, M. J.; Ator, M. A.; Bacon, E. R.; Mallamo, J. P.; Williams, M. CEP-26401 (Irdabisant), a potent and selective histamine H3 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J. Pharmacol. Exp. Ther. 2012, 340,124–133.


Page 48 of 51

Page 49 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


26. Nirogi, R.; Shinde, A.; Tiriveedhi, V.; Kota, L.; Saraf, S. K.; Badange, R. K.; Mohammed, A. R.; Subramanian, R.; Muddana, N.; Bhyrapuneni, G.; Abraham, R. Benzamide derivatives and their constrained analogs as histamine H3 receptor antagonists. Eur. J. Med. Chem. 2016, 108, 655–662. 27. Lovenberg, T. W.; Roland, B. L.; Wilson S. J. ; Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M. J.; Erlander, M. G. Cloning and functional expression of the human histamine H3 receptor. Molecular Pharmacol. 1999, 55, 1101–1107. 28. Ploemen, J.-P. H. T. M.; Kelder, J.; Hafmans, T.; van de Sandt, H.; van Burgsteden, J. A.; Salemink, P. J. M.; van Esch, E. Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines. Exp. Toxicol. Pathol. 2004, 55, 347–355. 29. Rouleau, A.; Ligneau, X.; Tardivel-Lacombe, J.; Morriset, S.; Gbahou, F.; Schwartz, J. C.; Arrang, J. M. Histamine H3-receptor mediated [35S]GTPS binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors. Br. J. Pharmacol.2002, 135, 383–392. 30. Clapham, J.; Kilpatrick, G. J. Histamine H3 receptor-mediated modulation of water consumption in the rat. Eur. J. Pharmacol. 1993, 232, 99–103. 31. Nirogi, R.; Kandikere, V.; Bhyrapuneni, G.; Muddana, N.; Saralaya, R.; Ponnamaneni, R.K.; Manoharan, A.K. In vivo receptor occupancy assay of histamine H3 receptor antagonist in rats using non-radiolabeled tracer. J. Pharmacol. Toxicol. Methods 2012, 65, 115–121. 32. Lin J. S.; Sergeeva O. A.; Haas H. L. Histamine H3 receptors and sleep-wake regulation. J. Pharmacol. Exp. Ther. 2011, 336, 17–23.



33. Barbier, A. J.; Berridge, C.; Dugovic, C.; Laposky, A. D.; Wilson, S. J.; Boggs, J.; Aluisio, L.; Lord, B.; Mazur, C.; Pudiak, C. M.; Langlois, X.; Xiao, W.; Apodaca, R.; Carruthers, N. I.; Lovenberg, T. W. Acute wake-promoting actions of JNJ-5207852, a novel, diaminebased H3 antagonist. Br. J. Pharmacol. 2004, 143, 649–661. 34. Lin, J. S.; Dauvilliers, Y.; Arnulf, I.; Bastuji, H.; Anaclet, C.; Parmentier, R.; Kocher, L.; Yanagisawa, M.; Lehert, P.; Ligneau, X.; Perrin, D.; Robert, P.; Roux, M.; Lecomte, J. M.; Schwartz, J. C. An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol. Dis. 2008, 30, 74–83. 35. Gerashchenko, D.; Kohls, M. D.; Greco, M.; Waleh, N. S.; Salin-Pascual, R.; Kilduff, T. S.; Lappi, D. A.; Shiromani, P. J.; Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J. Neurosci. 2001, 21, 7273–7283. 36. Kantor, S.; Mochizuki, T.; Janisiewicz, A. M.; Clark, E.; Nishino, S.; Scammell, T. E. Orexin neurons are necessary for the circadian control of REM sleep. Sleep 2009, 32, 1127–1134. 37. Nirogi, R.; Shinde, A. K.; Kambhampati R.; Jasti V. Process for large scale production of N-[4-(l-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride. U. S. Patent 9,802,896, Sep 14, 2017. 38. Lovenberg, T. W.; Roland, B. L.; Wilson, S. J.; Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M. R.; Erlander, M. G. Cloning and functional expression of the human histamine H3 receptor. Molecular Pharmacol. 1999, 55, 1101–1107. 39. Paxinos, G.; Watson, C. In the Rat Brain in Stereotaxic Coordinates, 5th ed.; Academic Press: Berlington, MA, USA, 2004.


Page 50 of 51

Page 51 of 51 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60


Table of Contents Graphic (TOC) N

O N

N

N O

Compound I

H N O

Iterative SAR, Physicochemical properties modulation

N O

O 2 HCl

Compound 17v (SUVN-G3031) hH3 Ki = 8.73 nM Rat i. v. t1/2 = 1.45 h Vdss (L/Kg) = 5 pKa = 8.50, 4.90 Wake promoting activity No addiction liability

hH3 Ki = 0.8 nM Rat i. v. t1/2 = 23.5 h Vdss (L/Kg) = 13 pKa = 10.0, 7.17


[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2 ... - ACS Publications

Recommend Documents